Dr. Zsiros is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Elm And Carlton St
Buffalo, NY 14263Phone+1 716-845-2300Fax+1 716-845-7608
Summary
- Dr. Emese Zsiros is a gynecologic oncologist in Buffalo, NY and is affiliated with Roswell Park Comprehensive Cancer Center. She received her medical degree from University of Debrecen Medical and Health Science Center in Hungary, completed her Ob/GYN residency at Northwestern University in Chicago and her fellowship in Gynecologic Oncology at the University of Pennsylvania. She has been in practice 12 years. She also speaks multiple languages, including Hungarian and Spanish. She specializes in gynecologic oncology and minimally invasive / endoscopic surgery and is experienced in gynecologic oncology, tumor immunotherapy, clinical research, minimally invasive gynecologic surgery, and adoptive immunotherapy.
Education & Training
- University of Pennsylvania Health SystemFellowship, Gynecologic Oncology, 2011 - 2013
- McGaw Medical Center of Northwestern UniversityResidency, Obstetrics and Gynecology, 2007 - 2011
- University of Debrecen Medical and Health Science CenterClass of 2005
Certifications & Licensure
- NY State Medical License 2014 - 2025
- PA State Medical License 2011 - 2016
- IL State Medical License 2010 - 2011
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Clinical Trials
- Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2016 Sep 01
- Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2017 Jun 27
- Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2023 Dec 15
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 46 citationsThe Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive TherapyEmese Zsiros, Priyanka Duttagupta, Denarda Dangaj, Hongzhe Li, Renee Frank
Clinical Cancer Research. 2015-02-23 - 357 citationsOvarian cancer, version 2.2020Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht
Journal of the National Comprehensive Cancer Network. 2021-02-02 - 276 citationsBladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.Thomas W Flaig, Philippe E Spiess, Neeraj Agarwal, Rick Bangs, Stephen A Boorjian
Journal of the National Comprehensive Cancer Network. 2020-03-01
Press Mentions
- NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024September 16th, 2024
- More Evidence to Support Restrictive Opioid Prescribing After Cancer SurgeryJanuary 6th, 2023
- Restrictive Opioid Prescription Protocol Feasible for Most Patients After Cancer SurgeryJanuary 5th, 2023
- Join now to see all
Professional Memberships
- Fellow
- Member
- Society of Gynecologic OncologyMember
- Member
- Member
Other Languages
- Hungarian, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: